{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T04:51:26Z","timestamp":1790743886262,"version":"4.1.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T00:00:00Z","timestamp":1659916800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T00:00:00Z","timestamp":1659916800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Universit\u00e4tsklinikum Hamburg-Eppendorf (UKE)"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Rheumatol Int"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Dermatomyositis is a rare, type I interferon-driven autoimmune disease, which can affect muscle, skin and internal organs (especially the pulmonary system). In 2021, we have noted an increase in new-onset dermatomyositis compared to the years before the SARS-CoV-2 pandemic in our center. We present four cases of new-onset NXP2 and\/or MDA5 positive dermatomyositis shortly after SARS-CoV-2 infection or vaccination. Three cases occurred within days after vaccination with Comirnaty and one case after SARS-CoV-2 infection. All patients required intensive immunosuppressive treatment. MDA5 antibodies could be detected in three patients and NXP2 antibodies were found in two patients (one patient was positive for both antibodies). In this case-based systematic review, we further analyze and discuss the literature on SARS-CoV-2 and associated dermatomyositis. In the literature, sixteen reports (with a total of seventeen patients) of new-onset dermatomyositis in association with a SARS-CoV-2 infection or vaccination were identified. Ten cases occurred after infection and seven after vaccination. All vaccination-associated cases were seen in mRNA vaccines. The reported antibodies included for instance MDA5, NXP2, Mi-2 and TIF1\u03b3. The reviewed literature and our cases suggest that SARS-CoV-2 infection and vaccination may be considered as a potential trigger of interferon-pathway. Consequently, this might serve as a stimulus for the production of dermatomyositis-specific autoantibodies like MDA5 and NXP2 which are closely related to viral defense or viral RNA interaction supporting the concept of infection and vaccination associated dermatomyositis.<\/jats:p>","DOI":"10.1007\/s00296-022-05176-3","type":"journal-article","created":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T08:03:36Z","timestamp":1659945816000},"page":"2267-2276","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["New-onset dermatomyositis following SARS-CoV-2 infection and vaccination: a case-based review"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2064-6728","authenticated-orcid":false,"given":"Marie-Therese","family":"Holzer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Krusche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikolas","family":"Ruffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heinrich","family":"Haberstock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marlene","family":"Stephan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tobias B.","family":"Huber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ina","family":"K\u00f6tter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,8]]},"reference":[{"key":"5176_CR1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.24786","author":"VL Kronzer","year":"2021","unstructured":"Kronzer VL, Kimbrough BA, Crowson CS et al (2021) Incidence, prevalence, and mortality of dermatomyositis: a population-based cohort study. Arthritis Care Res (Hoboken). https:\/\/doi.org\/10.1002\/acr.24786","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"5176_CR2","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1016\/j.jaad.2019.06.1309","volume":"82","author":"ME DeWane","year":"2020","unstructured":"DeWane ME, Waldman R, Lu J (2020) Dermatomyositis: clinical features and pathogenesis. J Am Acad Dermatol 82:267\u2013281. https:\/\/doi.org\/10.1016\/j.jaad.2019.06.1309","journal-title":"J Am Acad Dermatol"},{"key":"5176_CR3","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1002\/ana.20464","volume":"57","author":"SA Greenberg","year":"2005","unstructured":"Greenberg SA, Pinkus JL, Pinkus GS et al (2005) Interferon-alpha\/beta-mediated innate immune mechanisms in dermatomyositis. Ann Neurol 57:664\u2013678. https:\/\/doi.org\/10.1002\/ana.20464","journal-title":"Ann Neurol"},{"key":"5176_CR4","doi-asserted-by":"publisher","first-page":"59","DOI":"10.2119\/2006-00085.Baechler","volume":"13","author":"EC Baechler","year":"2007","unstructured":"Baechler EC, Bauer JW, Slattery CA et al (2007) An interferon signature in the peripheral blood of dermatomyositis patients is associated with disease activity. Mol Med 13:59\u201368. https:\/\/doi.org\/10.2119\/2006-00085.Baechler","journal-title":"Mol Med"},{"key":"5176_CR5","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1093\/rheumatology\/keaa033","volume":"59","author":"N Ono","year":"2020","unstructured":"Ono N, Kai K, Maruyama A et al (2020) The relationship between type 1 IFN and vasculopathy in anti-MDA5 antibody-positive dermatomyositis patients. Rheumatology (Oxford) 59:918. https:\/\/doi.org\/10.1093\/rheumatology\/keaa033","journal-title":"Rheumatology (Oxford)"},{"key":"5176_CR6","doi-asserted-by":"publisher","first-page":"631","DOI":"10.55563\/clinexprheumatol\/44kaji","volume":"39","author":"Y Kondo","year":"2021","unstructured":"Kondo Y, Kaneko Y, Takei H et al (2021) COVID-19 shares clinical features with anti-melanoma differentiation-associated protein 5 positive dermatomyositis and adult Still\u2019s disease. Clin Exp Rheumatol 39:631\u2013638","journal-title":"Clin Exp Rheumatol"},{"key":"5176_CR7","doi-asserted-by":"publisher","first-page":"3411","DOI":"10.1111\/ene.14564","volume":"28","author":"L Pitscheider","year":"2021","unstructured":"Pitscheider L, Karolyi M, Burkert FR et al (2021) Muscle involvement in SARS-CoV-2 infection. Eur J Neurol 28:3411\u20133417. https:\/\/doi.org\/10.1111\/ene.14564","journal-title":"Eur J Neurol"},{"key":"5176_CR8","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1001\/jamaneurol.2021.2004","volume":"78","author":"T Aschman","year":"2021","unstructured":"Aschman T, Schneider J, Greuel S et al (2021) Association between SARS-CoV-2 infection and immune-mediated myopathy in patients who have died. JAMA Neurol 78:948\u2013960. https:\/\/doi.org\/10.1001\/jamaneurol.2021.2004","journal-title":"JAMA Neurol"},{"key":"5176_CR9","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1097\/BOR.0000000000000844","volume":"33","author":"M de Santis","year":"2021","unstructured":"de Santis M, Isailovic N, Motta F et al (2021) Environmental triggers for connective tissue disease: the case of COVID-19 associated with dermatomyositis-specific autoantibodies. Curr Opin Rheumatol 33:514\u2013521. https:\/\/doi.org\/10.1097\/BOR.0000000000000844","journal-title":"Curr Opin Rheumatol"},{"key":"5176_CR10","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/nrd.2017.243","volume":"17","author":"N Pardi","year":"2018","unstructured":"Pardi N, Hogan MJ, Porter FW et al (2018) mRNA vaccines\u2014a new era in vaccinology. Nat Rev Drug Discov 17:261\u2013279. https:\/\/doi.org\/10.1038\/nrd.2017.243","journal-title":"Nat Rev Drug Discov"},{"key":"5176_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2021.108765","volume":"229","author":"PA Ntouros","year":"2021","unstructured":"Ntouros PA, Vlachogiannis NI, Pappa M et al (2021) Effective DNA damage response after acute but not chronic immune challenge: SARS-CoV-2 vaccine versus systemic lupus erythematosus. Clin Immunol 229:108765. https:\/\/doi.org\/10.1016\/j.clim.2021.108765","journal-title":"Clin Immunol"},{"key":"5176_CR12","doi-asserted-by":"publisher","DOI":"10.1111\/imm.13443","author":"Y Chen","year":"2021","unstructured":"Chen Y, Xu Z, Wang P et al (2021) New-onset autoimmune phenomena post COVID-19 vaccination. Immunology. https:\/\/doi.org\/10.1111\/imm.13443","journal-title":"Immunology"},{"key":"5176_CR13","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13256-022-03266-1","volume":"16","author":"K Vutipongsatorn","year":"2022","unstructured":"Vutipongsatorn K, Isaacs A, Farah Z (2022) Inflammatory myopathy occurring shortly after severe acute respiratory syndrome coronavirus 2 vaccination: two case reports. J Med Case Rep 16:57. https:\/\/doi.org\/10.1186\/s13256-022-03266-1","journal-title":"J Med Case Rep"},{"key":"5176_CR14","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1002\/art.40320","volume":"69","author":"IE Lundberg","year":"2017","unstructured":"Lundberg IE, Tj\u00e4rnlund A, Bottai M et al (2017) 2017 European league against rheumatism\/American college of rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Arthritis Rheumatol 69:2271\u20132282. https:\/\/doi.org\/10.1002\/art.40320","journal-title":"Arthritis Rheumatol"},{"key":"5176_CR15","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s41927-021-00225-z","volume":"5","author":"M Keshtkarjahromi","year":"2021","unstructured":"Keshtkarjahromi M, Chhetri S, Balagani A et al (2021) Macrophage activation syndrome in MDA5 antibody-positive dermatomyositis and COVID-19 infection. BMC Rheumatol 5:59. https:\/\/doi.org\/10.1186\/s41927-021-00225-z","journal-title":"BMC Rheumatol"},{"key":"5176_CR16","doi-asserted-by":"publisher","DOI":"10.1136\/postgradmedj-2022-141510","author":"AYS Lee","year":"2022","unstructured":"Lee AYS, Lee C, Brown DA et al (2022) Development of anti-NXP2 dermatomyositis following Comirnaty COVID-19 vaccination. Postgrad Med J. https:\/\/doi.org\/10.1136\/postgradmedj-2022-141510","journal-title":"Postgrad Med J"},{"key":"5176_CR17","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keab872","author":"Y Okada","year":"2021","unstructured":"Okada Y, Izumi R, Hosaka T et al (2021) Anti-NXP2 antibody-positive dermatomyositis developed after COVID-19 manifesting as type I interferonopathy. Rheumatology (Oxford). https:\/\/doi.org\/10.1093\/rheumatology\/keab872","journal-title":"Rheumatology (Oxford)"},{"key":"5176_CR18","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jdcr.2021.04.036","volume":"13","author":"BVK Ho","year":"2021","unstructured":"Ho BVK, Seger EW, Kollmann K et al (2021) Dermatomyositis in a COVID-19 positive patient. JAAD Case Rep 13:97\u201399. https:\/\/doi.org\/10.1016\/j.jdcr.2021.04.036","journal-title":"JAAD Case Rep"},{"key":"5176_CR19","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1186\/s41927-022-00250-6","volume":"6","author":"A Camargo Coronel","year":"2022","unstructured":"Camargo Coronel A, Jim\u00e9nez Balderas FJ, Qui\u00f1ones Moya H et al (2022) Dermatomyositis post vaccine against SARS-COV2. BMC Rheumatol 6:20. https:\/\/doi.org\/10.1186\/s41927-022-00250-6","journal-title":"BMC Rheumatol"},{"key":"5176_CR20","first-page":"20","volume":"68","author":"Y Gokhale","year":"2020","unstructured":"Gokhale Y, Patankar A, Holla U et al (2020) Dermatomyositis during COVID-19 pandemic (a case series): is there a cause effect relationship? J Assoc Physicians India 68:20\u201324","journal-title":"J Assoc Physicians India"},{"key":"5176_CR21","doi-asserted-by":"publisher","first-page":"e32","DOI":"10.3346\/jkms.2022.37.e32","volume":"37","author":"W Gouda","year":"2022","unstructured":"Gouda W, Albasri A, Alsaqabi F et al (2022) Dermatomyositis following BNT162b2 mRNA COVID-19 vaccination. J Korean Med Sci 37:e32\u2013e32. https:\/\/doi.org\/10.3346\/jkms.2022.37.e32","journal-title":"J Korean Med Sci"},{"key":"5176_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2022.02.023","author":"M Wu","year":"2022","unstructured":"Wu M, Karim M, Ashinoff R (2022) COVID-19 vaccine associated dermatomyositis. JAAD Case Rep. https:\/\/doi.org\/10.1016\/j.jdcr.2022.02.023","journal-title":"JAAD Case Rep"},{"key":"5176_CR23","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.pediatrneurol.2021.05.011","volume":"121","author":"E Liquidano-Perez","year":"2021","unstructured":"Liquidano-Perez E, Garc\u00eda-Romero MT, Yamazaki-Nakashimada M et al (2021) Juvenile dermatomyositis triggered by SARS-CoV-2. Pediatr Neurol 121:26\u201327. https:\/\/doi.org\/10.1016\/j.pediatrneurol.2021.05.011","journal-title":"Pediatr Neurol"},{"key":"5176_CR24","doi-asserted-by":"publisher","DOI":"10.1111\/dth.15479","author":"K Venkateswaran","year":"2022","unstructured":"Venkateswaran K, Aw DC-W, Huang J et al (2022) Dermatomyositis following COVID-19 vaccination. Dermatol Ther. https:\/\/doi.org\/10.1111\/dth.15479","journal-title":"Dermatol Ther"},{"key":"5176_CR25","doi-asserted-by":"publisher","first-page":"e04931","DOI":"10.1002\/ccr3.4931","volume":"9","author":"M Shahidi Dadras","year":"2021","unstructured":"Shahidi Dadras M, Rakhshan A, Ahmadzadeh A et al (2021) Dermatomyositis-lupus overlap syndrome complicated with cardiomyopathy after SARS-CoV-2 infection: a new potential trigger for musculoskeletal autoimmune disease development. Clin Case Rep 9:e04931\u2013e04931. https:\/\/doi.org\/10.1002\/ccr3.4931","journal-title":"Clin Case Rep"},{"key":"5176_CR26","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s10875-021-01119-y","volume":"42","author":"MP Rodero","year":"2022","unstructured":"Rodero MP, Pelleau S, Welfringer-Morin A et al (2022) Onset and relapse of juvenile dermatomyositis following asymptomatic SARS-CoV-2 infection. J Clin Immunol 42:25\u201327. https:\/\/doi.org\/10.1007\/s10875-021-01119-y","journal-title":"J Clin Immunol"},{"key":"5176_CR27","doi-asserted-by":"publisher","first-page":"SI96","DOI":"10.1093\/rheumatology\/keab290","volume":"60","author":"NH Borges","year":"2021","unstructured":"Borges NH, Godoy TM, Kahlow BS (2021) Onset of dermatomyositis in close association with COVID-19-a first case reported. Rheumatology (Oxford) 60:SI96. https:\/\/doi.org\/10.1093\/rheumatology\/keab290","journal-title":"Rheumatology (Oxford)"},{"key":"5176_CR28","doi-asserted-by":"publisher","first-page":"A445","DOI":"10.1016\/j.revmed.2021.10.186","volume":"42","author":"A Derbel","year":"2021","unstructured":"Derbel A, Guermazi M, El Moctar EM et al (2021) Dermatomyositis following COVID-19 infection. Rev Med Interne 42:A445. https:\/\/doi.org\/10.1016\/j.revmed.2021.10.186","journal-title":"Rev Med Interne"},{"key":"5176_CR29","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.18211","author":"A Kreuter","year":"2022","unstructured":"Kreuter A, Lausch S, Burmann S-N et al (2022) Onset of amyopathic dermatomyositis following mRNA-based SARS-CoV-2 vaccination. J Eur Acad Dermatol Venereol n\/a. https:\/\/doi.org\/10.1111\/jdv.18211","journal-title":"J Eur Acad Dermatol Venereol n\/a"},{"key":"5176_CR30","doi-asserted-by":"publisher","first-page":"434","DOI":"10.21037\/atm-20-3719","volume":"9","author":"CE Bax","year":"2021","unstructured":"Bax CE, Maddukuri S, Ravishankar A et al (2021) Environmental triggers of dermatomyositis: a narrative review. Ann Transl Med 9:434. https:\/\/doi.org\/10.21037\/atm-20-3719","journal-title":"Ann Transl Med"},{"key":"5176_CR31","doi-asserted-by":"publisher","first-page":"102788","DOI":"10.1016\/j.autrev.2021.102788","volume":"20","author":"S Toquet","year":"2021","unstructured":"Toquet S, Granger B, Uzunhan Y et al (2021) The seasonality of dermatomyositis associated with anti-MDA5 antibody: an argument for a respiratory viral trigger. Autoimmun Rev 20:102788. https:\/\/doi.org\/10.1016\/j.autrev.2021.102788","journal-title":"Autoimmun Rev"},{"key":"5176_CR32","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s12969-021-00570-w","volume":"19","author":"N Movahedi","year":"2021","unstructured":"Movahedi N, Ziaee V (2021) COVID-19 and myositis; true dermatomyositis or prolonged post viral myositis? Pediatr Rheumatol Online J 19:86. https:\/\/doi.org\/10.1186\/s12969-021-00570-w","journal-title":"Pediatr Rheumatol Online J"},{"key":"5176_CR33","doi-asserted-by":"publisher","first-page":"10023","DOI":"10.1128\/JVI.01530-15","volume":"89","author":"S Ver Lorena","year":"2015","unstructured":"Ver Lorena S, Marcos-Villar L, Landeras-Bueno S et al (2015) The cellular factor NXP2\/MORC3 is a positive regulator of influenza virus multiplication. J Virol 89:10023\u201310030. https:\/\/doi.org\/10.1128\/JVI.01530-15","journal-title":"J Virol"},{"key":"5176_CR34","doi-asserted-by":"publisher","first-page":"108628","DOI":"10.1016\/j.celrep.2020.108628","volume":"34","author":"X Yin","year":"2021","unstructured":"Yin X, Riva L, Pu Y et al (2021) MDA5 governs the innate immune response to SARS-CoV-2 in lung epithelial cells. Cell Rep 34:108628. https:\/\/doi.org\/10.1016\/j.celrep.2020.108628","journal-title":"Cell Rep"},{"key":"5176_CR35","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1007\/s00296-021-04819-1","volume":"41","author":"P Mehta","year":"2021","unstructured":"Mehta P, Machado PM, Gupta L (2021) Understanding and managing anti-MDA 5 dermatomyositis, including potential COVID-19 mimicry. Rheumatol Int 41:1021\u20131036. https:\/\/doi.org\/10.1007\/s00296-021-04819-1","journal-title":"Rheumatol Int"},{"key":"5176_CR36","doi-asserted-by":"publisher","first-page":"791348","DOI":"10.3389\/fimmu.2021.791348","volume":"12","author":"G Wang","year":"2021","unstructured":"Wang G, Wang Q, Wang Y et al (2021) Presence of anti-MDA5 antibody and its value for the clinical assessment in patients with COVID-19: a retrospective cohort study. Front Immunol 12:791348","journal-title":"Front Immunol"},{"key":"5176_CR37","doi-asserted-by":"publisher","first-page":"420","DOI":"10.5114\/reum.2021.111836","volume":"59","author":"K Gupta","year":"2021","unstructured":"Gupta K, Sharma GS, Kumar A (2021) COVID-19 vaccination-associated anti-Jo-1 syndrome. Reumatologia 59:420\u2013422. https:\/\/doi.org\/10.5114\/reum.2021.111836","journal-title":"Reumatologia"},{"key":"5176_CR38","doi-asserted-by":"publisher","first-page":"2389","DOI":"10.1056\/NEJMc2031085","volume":"383","author":"GS Manzano","year":"2020","unstructured":"Manzano GS, Woods JK, Amato AA (2020) Covid-19-associated myopathy caused by type I interferonopathy. N Engl J Med 383:2389\u20132390. https:\/\/doi.org\/10.1056\/NEJMc2031085","journal-title":"N Engl J Med"},{"key":"5176_CR39","doi-asserted-by":"publisher","first-page":"e849","DOI":"10.1212\/WNL.0000000000012344","volume":"97","author":"J Suh","year":"2021","unstructured":"Suh J, Mukerji SS, Collens SI et al (2021) Skeletal muscle and peripheral nerve histopathology in COVID-19. Neurology 97:e849. https:\/\/doi.org\/10.1212\/WNL.0000000000012344","journal-title":"Neurology"},{"key":"5176_CR40","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1007\/s13167-017-0101-y","volume":"8","author":"M Vadal\u00e0","year":"2017","unstructured":"Vadal\u00e0 M, Poddighe D, Laurino C et al (2017) Vaccination and autoimmune diseases: is prevention of adverse health effects on the horizon? EPMA J 8:295\u2013311. https:\/\/doi.org\/10.1007\/s13167-017-0101-y","journal-title":"EPMA J"},{"key":"5176_CR41","doi-asserted-by":"publisher","DOI":"10.1002\/9781118663721.ch37","volume-title":"Myositis and Vaccines","author":"I Rodriguez-Pint\u00f3","year":"2015","unstructured":"Rodriguez-Pint\u00f3 I, Shoenfeld Y (2015) Myositis and Vaccines. Wiley Online Books, Hoboken"},{"key":"5176_CR42","doi-asserted-by":"publisher","first-page":"1213","DOI":"10.1177\/0961203309345734","volume":"18","author":"H Orbach","year":"2009","unstructured":"Orbach H, Tanay A (2009) Vaccines as a trigger for myopathies. Lupus 18:1213\u20131216. https:\/\/doi.org\/10.1177\/0961203309345734","journal-title":"Lupus"},{"key":"5176_CR43","doi-asserted-by":"publisher","first-page":"3790","DOI":"10.1016\/j.vaccine.2021.05.087","volume":"39","author":"S Abu Mouch","year":"2021","unstructured":"Abu Mouch S, Roguin A, Hellou E et al (2021) Myocarditis following COVID-19 mRNA vaccination. Vaccine 39:3790\u20133793. https:\/\/doi.org\/10.1016\/j.vaccine.2021.05.087","journal-title":"Vaccine"},{"key":"5176_CR44","doi-asserted-by":"publisher","first-page":"2092","DOI":"10.1056\/NEJMoa2104840","volume":"384","author":"A Greinacher","year":"2021","unstructured":"Greinacher A, Thiele T, Warkentin TE et al (2021) Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination. N Engl J Med 384:2092\u20132101. https:\/\/doi.org\/10.1056\/NEJMoa2104840","journal-title":"N Engl J Med"},{"key":"5176_CR45","doi-asserted-by":"publisher","first-page":"102741","DOI":"10.1016\/j.jaut.2021.102741","volume":"125","author":"I Garrido","year":"2021","unstructured":"Garrido I, Lopes S, Sim\u00f5es MS et al (2021) Autoimmune hepatitis after COVID-19 vaccine\u2014more than a coincidence. J Autoimmun 125:102741. https:\/\/doi.org\/10.1016\/j.jaut.2021.102741","journal-title":"J Autoimmun"},{"key":"5176_CR46","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1053\/j.ajkd.2021.06.016","volume":"78","author":"MT Shakoor","year":"2021","unstructured":"Shakoor MT, Birkenbach MP, Lynch M (2021) ANCA-associated vasculitis following Pfizer-BioNTech COVID-19 vaccine. Am J Kidney Dis 78:611\u2013613. https:\/\/doi.org\/10.1053\/j.ajkd.2021.06.016","journal-title":"Am J Kidney Dis"},{"key":"5176_CR47","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1016\/j.jaad.2021.07.054","volume":"85","author":"S Wack","year":"2021","unstructured":"Wack S, Patton T, Ferris LK (2021) COVID-19 vaccine safety and efficacy in patients with immune-mediated inflammatory disease: review of available evidence. J Am Acad Dermatol 85:1274\u20131284. https:\/\/doi.org\/10.1016\/j.jaad.2021.07.054","journal-title":"J Am Acad Dermatol"},{"key":"5176_CR48","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1186\/s12929-020-00695-2","volume":"27","author":"Y-D Li","year":"2020","unstructured":"Li Y-D, Chi W-Y, Su J-H et al (2020) Coronavirus vaccine development: from SARS and MERS to COVID-19. J Biomed Sci 27:104. https:\/\/doi.org\/10.1186\/s12929-020-00695-2","journal-title":"J Biomed Sci"},{"key":"5176_CR49","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.4103\/0366-6999.180528","volume":"129","author":"X Yin","year":"2016","unstructured":"Yin X, Han G-C, Jiang X-W et al (2016) Increased expression of the NOD-like receptor family, pyrin domain containing 3 inflammasome in dermatomyositis and polymyositis is a potential contributor to their pathogenesis. Chin Med J (Engl) 129:1047\u20131052. https:\/\/doi.org\/10.4103\/0366-6999.180528","journal-title":"Chin Med J (Engl)"},{"key":"5176_CR50","doi-asserted-by":"publisher","first-page":"e14150","DOI":"10.15252\/emmm.202114150","volume":"13","author":"SJ Theobald","year":"2021","unstructured":"Theobald SJ, Simonis A, Georgomanolis T et al (2021) Long-lived macrophage reprogramming drives spike protein-mediated inflammasome activation in COVID-19. EMBO Mol Med 13:e14150. https:\/\/doi.org\/10.15252\/emmm.202114150","journal-title":"EMBO Mol Med"},{"key":"5176_CR51","doi-asserted-by":"publisher","first-page":"851620","DOI":"10.3389\/fimmu.2022.851620","volume":"13","author":"T Won","year":"2022","unstructured":"Won T, Gilotra NA, Wood MK et al (2022) Increased interleukin 18-dependent immune responses are associated with myopericarditis after COVID-19 mRNA vaccination. Front Immunol 13:851620","journal-title":"Front Immunol"}],"container-title":["Rheumatology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-022-05176-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00296-022-05176-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00296-022-05176-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T11:50:27Z","timestamp":1665402627000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00296-022-05176-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,8]]},"references-count":51,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["5176"],"URL":"https:\/\/doi.org\/10.1007\/s00296-022-05176-3","relation":{},"ISSN":["1437-160X"],"issn-type":[{"value":"1437-160X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,8]]},"assertion":[{"value":"6 May 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"This manuscript does not contain human or animal studies. All patients gave written consent to anonymously publishing their cases, including pictures, in which the patients can\u2019t be identified.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Standard"}}]}}